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MyometriumMicroRNAs (miRNAs) are a class of small non-coding RNAs, which are negative regulators of gene expression.
Many genes in human uterine leiomyoma (ULM) are aberrantly expressed and in some cases this can be due
to dysregulation of miRNAs. Here we present the ﬁrst study to determine genome-wide miRNA expression
patterns in uterine leiomyoma and myometrium using Solexa high-throughput sequencing. We found
more than 50 miRNAs, which were differentially expressed, and furthermore we extend the list of putative
new miRNA genes. The top ﬁve signiﬁcantly de-regulated miRNAs in ULMs that we found in our libraries
were miR-363, miR-490, miR-137, miR-217 and miR-4792. We also observed “isomiRs” with higher copy
number than referenced mature miRNA speciﬁc for the leiomyoma libraries, which have a potential role in
tumorigenesis. The microRNA transcriptomes obtained in this study deliver insights and further expand
our understanding the role of small RNAs in uterine leiomyoma development.
© 2012 Elsevier Inc. All rights reserved.1. Introduction
MicroRNAs (miRNAs) are a new class of negative regulators that
repress gene expression by binding with their target messenger
RNAs (mRNAs). Through this pairing to the 3′UTR of mRNAs, miRNAs
trigger degradation of the target transcript or inhibition of protein
translation [1,2]. Biogenesis of miRNA involves several steps. Firstly,
miRNA genes are transcribed by RNA polymerase II into primary
RNA (pri-miRNA) molecule. The pri-miRNA is subsequently cleaved in
the nucleus by anRNase III endonuclease, Drosha, forming a 70–100 nu-
cleotide (nt) hairpin loop structure known as precursor miRNA. Next,
the pre-miRNA is exported into the cytoplasm and further processed,
by Dicer, into a double stranded RNA duplex with 3′-overhangs [3–5].
Based on the thermodynamic stability of this duplex, one of the strands
is selected as the biologically active mature miRNA whilst the other,
known as the passenger strand or miRNA star, is typically degraded [6].
The mature miRNAs are short (20–24 nt) single stranded RNAs that,
together with Argonaute proteins, mediate direct post-transcriptional
regulation. miRNAs are essential for normal mammalian development
and regulate genes involved in cell division and differentiation, metabo-
lism, stress response and apoptosis [7]. miRNAs have been shown to
regulate oncogenes, tumor-suppressors and a number of cancer-
related genes, therefore their deregulation can predispose to disease
and malignancies [8,9]. Most importantly, different cancer types, and
stages exhibit unique miRNA expression patterns, suggesting thatrights reserved.miRNA genes can function as novel biomarkers for cancer diagnosis
[8,10,11]. Moreover, miRNA signatures are also altered in variety of be-
nign tumors such as human uterine leiomyomas (ULMs) [12–14].
Leiomyomata uteri or ﬁbroids are the most common neoplasm of
the female genital tract developing primarily during the reproductive
years and becoming symptomatic during perimenopause [15–18]. Tu-
mors occur in approximately 80% of women, and approximately 25%
of Caucasians have clinically signiﬁcant, symptomatic lesions. Most
affected women have multiple tumors with the average number of
tumors per uterus estimated to be 6.5 [19]. The relative risk of ﬁbroids
is two to threefold greater in blackwomen thanwhitewomenand clinical
disease is more severe in the former [20]. The biological sequelae of ﬁ-
broids manifest as a spectrum of clinical symptoms, primarily pain
and excessive menstrual bleeding. Reproductive issues are also a con-
cern, as ﬁbroids are associated with infertility and, if present during
pregnancy, may contribute to second trimester pregnancy losses, pre-
mature labor, fetal malpresentations and/or distocia. Despite the sig-
niﬁcant impact on women's health, the etiology of ﬁbroids remains
poorly understood and only a few speciﬁc genes have been identiﬁed
to be associated with development of this tumor.
Little is known about the repertoire and function of miRNA in human
uterine leiomyoma. Several studies have assessed levels of subsets of
miRNAs throughmicroarray expression analysis [12–14], demonstrating
that many miRNAs are deregulated in leiomyoma compared to normal
tissue. To proﬁle the small RNAome in leiomyomas andmyometrium is-
sues and to reveal deeper insights into miRNAs expression changes be-
tween diseased and normal states, we used Solexa high-throughput
sequencing technology. This method has signiﬁcant advantages
over microarray and PCR-based assays in characterizing the miRNA
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limited by array content and thus allows identiﬁcation of novelmiRNAs.
Moreover, parallel sequencing has the ability to identify low abundance
miRNAs and affords an opportunity for detection of small differences in
miRNAs expression between samples [21].
To the best of our knowledge, the differential expression of miRNAs
has not been studied via deep-sequencing in ULMs. In this manuscript
we used next-generation sequencing to characterize small RNA transcrip-
tome, to compare expression signatures of knownmiRNAs in leiomyoma
versus matched normal myometrium and to discover novel miRNAs. We
were able to identify more than 50miRNAs exhibiting altered expression
and 25 genomic loci that encode putative novel miRNA genes, thus
expanding the list ofmiRNAs representing the unique signature of uterine
leiomyomas.
2. Results
2.1. Overview — sequencing statistics, lengths and reads
By using Solexa technology, a newly developed method for high-
throughput sequencing producing highly accurate and quantitative read-
outs of small RNA, four libraries of small RNAs frommyometrium (B25N
and B27N) and leiomyoma (B25L and B27L) were established and
sequenced. After applying reads ﬁlters and discarding low quality reads,
adaptor sequences were trimmed. Additionally, reads attributed to
ligation contaminants or self-ligation of the adaptorswere also discarded.
We obtained 7,284,165 (B25N) and 5,506,769 (B27N) clean reads from
normal myometrium and −7,629,120 (B25L) and 7,423,663 (B27L)
from leiomyoma libraries. For the small RNA analysis we further clus-
tered all raw reads into unique sequences with associate copy numbers
generating 74,547 (B25N), 48,114 (B27N), 45,538 (B25L) and 59,148
(B27L) unique tags from normal myometrium and leiomyoma samples,
respectively.
The length distribution of the high quality tags was consistent
among the four RNA libraries. In our analysis of small RNAs we selected
sequences in the range of 15 to 30 nt. Results showed that this resulted
in enrichment of miRNAs since the fraction of reads within the rangeFig. 1. The length distribution of small RNAs in leiomyoma (B220–22 nt (considered as a typicalmiRNA length) comprised themajority
(80–90%) in all four samples (Fig. 1). Interestingly, a signiﬁcant 23 nt
peak representing 1,237,791 of 7,423,663 reads (~17%) was observed
in sample B27L but not in the other libraries.2.2. Mapping and annotation of small RNAs
The 15–30 nt clean reads from four libraries were subsequently
aligned and mapped to the human genome allowing at most one mis-
match. Total mappable reads were approximately 99% in all sequencing
libraries. After clustering these mappable reads to unique sequences
they represented 67.51% (B25N), 66.58% (B27N), 59.34% (B25L) and
61.96% (B27L) of the sequences in myometrium and leiomyoma
samples, respectively. Based on the UCSC human genome annotation
and additional well-characterized RNA datasets (see Materials and
Methods) all small RNA sequences were annotated as known miRNAs,
degradation fragments from non-coding RNAs (tRNA, rRNA, snRNA/
snoRNA), genomic repeats, mRNAs (exons, introns) or unclassiﬁed.
The fraction of small RNAs derived from UTR regions of mRNA was
very small and therefore not included in our results.
As expected, themost abundant RNA category from the four libraries
was known miRNAs: 95% (B25N and B27N); 96% (B25L and B27L). The
remaining, less abundant categories were non-coding RNAs and repeat
elements. A minor fraction of small RNAs were mapped to coding-
sequences, which likely represent degradation products from mRNAs.
Read counts of the classiﬁed categories are summarized in Table 1.
Recent studies showed that some genomes can generate repeat
associated small RNAs, which can regulate retrotransposon expres-
sion. Yang et al., demonstrated that small interfering RNAs, which
are endogenously coded, can suppress the L1 retrotransposon in
human cell cultures [24]. Therefore, we additionally explored the reper-
toire of small RNAs that are aligned to genome repeats, and represent a
set of putative RNAs associated with transposable elements. In the
mammalian genome, transposon elements are mostly composed of
three major classes: LTR, LINE and SINE retrotransposons. Our results
revealed that the majority of reads mapping to repeat elements were5L and B27L) and myometrial (B25N and B27N) libraries.
Table 1
Classiﬁed small RNA species in four sequencing libraries.
Category B25N B25L B27N B27L
Unique Total Unique Total Unique Total Unique Total
Exon sense 5262 5895 1966 2302 2713 3396 3073 3796
Exon antisense 324 400 129 156 220 264 233 319
Intron sense 6477 14637 3858 5886 3730 6241 5325 9288
Intron antisense 1383 3617 764 1262 723 1427 1143 2782
lincRNA 2275 5553 1066 3658 1123 2097 1796 3845
miRNA 6363 6906338 4963 7304242 4344 5233252 5629 7084478
otherRNA 768 4417 455 3226 372 1235 587 2529
rRNA 6071 19538 1614 3984 3824 21272 3206 9171
snRNA 459 944 189 302 114 232 287 623
snoRNA 2317 15152 1305 6969 1242 7084 3240 15045
tRNA 1876 9162 1364 6985 1369 5565 1690 7684
Repeats sense 5199 10286 2924 5248 2970 5776 4213 9151
Repeats antisense 2656 8480 1337 3287 1325 3049 1967 4717
Unannotated 33117 279746 23604 281613 24045 215879 26759 270235
Total 74547 7284165 45538 7629120 48114 5506769 59148 7423663
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LTR-derived small RNAs (see Appendix A).
2.3. MicroRNA expression patterns
There are 1424 human miRNAs annotated in release 17 of miRBase
(Sept 2010). We detected approximately 25% of these miRNAs in
small RNA libraries derived from normal myometrium and leiomyoma.
A total number of 321 and 258 miRNAs were detected (with at least 5
read counts and not allowing mismatches in the mature sequence) in
normal tissue samples (B25N and B27N) and 283 and 295 across leio-
myoma samples (B25L and B27L), with 218 miRNA being common to
all libraries.
Expression abundance analysis, based on raw read copy numbers
(sequencing frequency) from sequencing, revealed that, in all four
samples miR-143 represented the most abundant tag in the libraries.
Other miRNAs detected at high copy number, based upon sequencing
frequency were miR-145, miR-27b, miR-21, let-7a, let-7f, miR-26a
and miR-125b (see Appendix C).
2.4. IsomiRs — variations in mature miRNA processing
miRNAs frequently exhibit differences from their “reference”mature
sequences, generating multiple variations that are called as “isomiRs”. In
many cases both mature miRNA and corresponding isomiRs were pre-
sent in the sequencing libraries. IsomiRs variability can be explained byFig. 2. Example of mature miRNA (miR-10b) in B25L showing 3′ and 5′ sequence variations
counts than the published mature sequence in miRbase (in red).the imprecise and alternative cleavage of Dicer and Drosha during pre-
miRNA hairpin processing. Such events have been observed in several
previous studies using high-throughput sequencing data [25–27]. Our
results revealed that many of the mature miRNAs in myometrium and
leiomyoma sequencing libraries possess isomiRs sequences. Moreover,
our analysis shows that several isomiRs have higher raw read copy
numbers, relative to their mature reference sequences indexed in
miRBase (Fig. 2). In the myometrium datasets we observed 49 (B25N)
and 43 (B27N) isomiRs that are more abundant than their mature refer-
encemiRNAand 44 (B25L) and 52 (B27L) in leiomyoma,with 23 isomiRs
being common to all libraries. 13 of the identiﬁed isomiRswere uniquely
over expressed in leiomyoma samples, whereas in control samples their
referenced mature miRNAs were present at a higher frequency (Appen-
dix D).2.5. Differential expression of known miRNAs between leiomyoma and
myometrium sequencing libraries
Microarray based methods have been extensively used to proﬁle
differential expression of known miRNAs at the genomic scale. To
date, the miRNA repertoire of uterine leiomyomas and their aberrant
expression, compared to normal myometrium, have been explored
mainly with such microarray technology [12–14]. There are few re-
ports describing analysis of differentially expressed miRNAs by
deep-sequencing technology and currently this approach has not
been used in uterine leiomyoma. Moreover, there are no standard(isomiRs). One of the observed isomiRs (in green) is showing considerably higher read
Table 2
Differential expression analysis of miRNAs detected by deep sequencing in leiomyoma
compared to myometrium samples. (A) A collection of signiﬁcantly deregulated miRNAs
in leiomyoma, taking into account all isomiR variations generated from themiRNAprecur-
sor. (B) Differentially expressed analysis of miRNAs by mature sequences referenced in
miRBase. miRNAs found by both methods are highlighted.
A B
miRNA name log2FoldChange miRNA name log2FoldChange
Up-regulated Up-regulated
hsa-mir-363 6.53 hsa-miR-363 6.13
hsa-mir-490 6.21 hsa-miR-135a 5.51
hsa-mir-137 6.01 hsa-miR-135b 4.69
hsa-mir-548y 5.14 hsa-miR-490-3p 4.48
hsa-mir-135b 4.75 hsa-miR-3607-3p 4.23
hsa-mir-135a-1 4.62 hsa-miR-885-5p 4.12
hsa-mir-135a-2 4.62 hsa-miR-136 3.76
hsa-mir-885 4.42 hsa-miR-106a 3.68
hsa-mir-187 4.34 hsa-miR-154* 3.67
hsa-mir-483 4.06 hsa-miR-153 3.33
hsa-mir-2682 3.87 hsa-miR-222 3.26
hsa-mir-153-1 3.61 hsa-miR-9 3.16
hsa-mir-488 3.56 hsa-miR-20b 3.15
hsa-mir-624 3.54 hsa-miR-200b 3.02
hsa-mir-200b 3.37 hsa-miR-488 3.00
hsa-mir-549 3.12 hsa-miR-378d 2.98
hsa-mir-429 3.09 hsa-miR-378* 2.98
hsa-mir-9-1 2.97 hsa-miR-582-5p 2.92
hsa-mir-9-2 2.97 hsa-miR-204 2.78
hsa-mir-9-3 2.97 hsa-miR-501-5p 2.22
hsa-mir-153-2 2.96 hsa-miR-542-5p 1.80
hsa-mir-219-2 2.83
hsa-mir-2964a 2.83
hsa-mir-4443 2.78
hsa-mir-200a 2.73
hsa-mir-204 2.68
hsa-mir-222 2.55
hsa-mir-582 2.43
hsa-mir-378b 2.33
hsa-mir-378h 2.32
hsa-mir-494 2.31
hsa-mir-422a 2.28
hsa-mir-376c 2.23
hsa-mir-378e 2.11
hsa-mir-376b 1.94
hsa-mir-21 1.26
Down-regulated Down-regulated
hsa-mir-320c-2 -1.93 hsa-miR-103a -2.20
hsa-mir-320c-1 -1.98 hsa-miR-100* -2.34
hsa-mir-877 -2.52 hsa-miR-101* -3.18
hsa-mir-183 -2.85 hsa-miR-320a -3.25
hsa-mir-935 -2.94 hsa-miR-29b-1* -3.25
hsa-mir-129-2 -2.99 hsa-miR-22* -3.47
hsa-mir-129-1 -3.01 hsa-miR-182 -3.61
hsa-mir-320a -3.05 hsa-miR-144* -3.66
hsa-mir-320b-2 -3.09 hsa-miR-27a* -3.67
hsa-mir-320b-1 -3.12 hsa-miR-497 -3.92
hsa-mir-497 -3.35 hsa-miR-320b -4.04
hsa-mir-182 -3.46 hsa-miR-451 -4.18
hsa-mir-144 -3.50 hsa-miR-590-3p -4.48
hsa-mir-3926-1 -3.55 hsa-miR-486-5p -4.85
hsa-mir-486 -3.58
hsa-mir-451 -3.92
hsa-mir-451b -3.92
hsa-mir-590 -4.39
hsa-mir-4792 -4.99
hsa-mir-217 -5.36
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quencing of small RNAs. In most cases expression level of miRNAs is
estimated by the frequency (copy number) of the mature miRNA
tag (referenced in miRBase). We have shown that many of the miRNAs
from our sequencing libraries have corresponding isomiR sequences
with higher copy number than their referenced mature sequence, im-
plying that these mature miRNA variations can be speciﬁc for different
tissues types or states. Recent studies suggest that expression diver-
gence, detected by analyzing the most abundant isomiRs and all iso-
miRs, respectively, can be a better marker of the relative expression in
deep-sequencing data [26,28]. Therefore, we used the intersection of
two methods to identify differentially expressed miRNAs: ﬁrstly, abso-
lute sequence read counts of the mature miRNA and star sequences
(miRbase v17) from each sample were used as a input data for the sta-
tistical software Deseq [29] specializing in normalization and differen-
tial expression analysis for NGS data (Table 2B); secondly, we took
into account all sequence variants generated from miRNA precursors
(pre-miRNA) along with referenced mature sequence, thus assigning
total number of read counts from all isomiRs; Subsequently, the total
counts for each miRNA precursor were again loaded in Deseq module
for analysis of expression divergence (Appendix B). The list of the differ-
entially expressed miRNAs (considering isomiR variations) is shown in
Table 2A.We identiﬁed 35 deregulatedmiRNAs by the ﬁrst method and
52 by the second (with P-valueb0.05 and |log2 ratio|≥1). Twenty-four
miRNAs were found to be differentially expressed by both approaches.
2.6. Prediction of novel miRNA genes
One of the important advantages of deep-sequencing of the small
RNA transcriptome is that it allows identiﬁcation of novel miRNAs. A
total of 24 novel miRNA candidates were predicted in a stepwise
manner using widely adopted software for identiﬁcation of miRNAs
from deep-sequencing datasets MIREAP and miRDeep (see Materials
andmethods). We analyzed our libraries separately with the two pro-
grams to gain independent results. We observed these 24 miRNAs
have a size range of 21–24 nt and the lengths of their predicted pre-
cursors vary from 73 to 112, which is consistent with known human
miRNAs. More than a half of the newly predicted candidates (14 miR-
NAs) were categorized as intronic, having genomic location within an
intron of host genes (Appendix E). Thirteen candidates were captured
in more than one sequencing library, and several were identiﬁed in all
four datasets. Notably many of the novel candidate miRNAs showed
homology to other mammalian mature miRNAs derived from canine
and rodent tissues (Cannisfamiliaris, Susscrofa and Ratusnorvegicus).
Piriyapongsa and colleagues demonstrated that members of a re-
cently described family of human miRNA genes, miR-548, are derived
from transposable elements. We observed 8 novel miRNAs that exhibit
sequence similarity to this family and their genomic loci overlapped
with transposon track in human genome (UCSC database) [30].
3. Discussion
In the present studywe used next-generation sequencing approaches
and bioinformatics methods to determine the differentially expressed
miRNAs in human leiomyoma and normal myometrium. So far, this is
the ﬁrst proﬁling study of miRNA changes associated with leiomyoma
uteri via high-throughput sequencing. Moreover we predicted 24 novel
miRNAs in the sequenced samples.
Recent studies using deep-sequencing of small RNAs from the female
reproductive tract showed that the let-7 family is one of the most abun-
dant in the miRNA pool [31]. Based on sequenced frequency in our sam-
ples, themost expressedmember of let-7 familywas let-7a. Interestingly,
we observed several miRNAs with higher expression levels. For example,
in all four samples, miR-143 represented the most abundant tag in the
libraries, with expression levels several fold higher than let-7a. MiRNAs
are often located in gene clusters and it is generally believed that inthese clusters miRNAs are co-regulated and co-transcribed [32]. Ac-
cordingly, we found very high relative expression levels of miR-145,
which forms part of the miR-143/145 cluster.
In addition to expression proﬁling in sequenced libraries, we ob-
served a diverse population of mature miRNA variants, known as “iso-
miRs”. Although the functional role of isomiRs remains unknown, they
have the potential to broaden the range of the miRNA regulatory net-
work. Since variation in isomiR sequence occurs at the 3′ and 5′-ends,
they could potentially bind to a different repertoire of targets relative
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are expressed at higher levels than their reference mature miRNA, the
target network of that particular miRNA can be altered. In this study
we were able to detect isomiRs of approximately 1/6 of all identiﬁed
miRNAs in each library. Notably, 13 miRNAs exhibited overexpression
of their cognate isomiRs, uniquely in leiomyoma. Therefore the observed
speciﬁc signature overabundance of isomiRs in the tumor samples, im-
plies a potential role in the aberrant regulation of protein-coding genes
that underlie leiomyoma pathogenesis and progression.
Like Guo and Lu [28], we think that analysis of isomiRs copy number
can contribute to the estimation of the miRNA relative expression level.
On that account, we evaluate the expression divergence of miRNAs by
copy number of mature miRNA sequence and additionally based on
sum of all isomiRs sequence counts. Our data showed several miRNAs
with a signiﬁcant up-regulation conﬁrming published studies. We
observed increased levels of miR-21 in leiomyoma, consistent with
previous reports [12,14,33]. Moreover, miR-21 stands out as the only
miRNA overexpressed in the vast majority of tumor types analyzed,
indicating that miR-21 is a key regulator of cell proliferation, survival
andmigration and tumorigenesis [34]. OthermiRNAs also reported pre-
viously to be differentially up-regulated are miR-483, miR-20b, miR-
494, miR-376b and miR-582 [12–14]. MiR-483, which is located in an
intron within the IGF2 gene, is overexpressed not only in leiomyoma,
but also in other tumors (pancreatic, colon, breast and liver cancers),
consistent with this miRNA being an important “oncomiR” [35–38].
Similarly, recent microarray analysis of miRNAs expression in uterine
leiomyoma also demonstrated overlap with our observations with re-
spect to down-regulated miRNAs. These include miR-217, miR-486,
miR-451, miR-144 and miR-320 [12–14]. Interestingly, we found three
members from the miR-320 cluster (miR-320a, miR-320b and miR-
320c) to exhibit a similar pattern of down-regulation in leiomyoma
libraries.
Our study identiﬁed many miRNAs that are reported here for the
ﬁrst time as differentially regulated in uterine leiomyoma comparing
to normal myometrium. Some of them are mentioned in the literature
as important tumor-related miRNAs, and we postulate that they may
also play an essential role in leiomyoma formation. For example, we
found miR-200a/b and miR-429 (belonging to the same family) to be
up-regulated in leiomyoma. Snowdon and co-workers reported that
the entiremiR-200 familywas overexpressed in endometrial carcinoma
[39]. Moreover increased expression of miR-200b was also observed in
ovarian, pancreatic, prostate and breast cancer [40–43].
In summary, we have investigated the miRNA expression proﬁles in
human uterine leiomyoma and normal myometrium using a small RNA
deep-sequencing approach. We identiﬁed a number of miRNAs that
were signiﬁcantly differentially expressed in ﬁbroids, consistent with
previous studies. In addition, we detected several novel putative miR-
NAs and unique patterns of isomiRs expression, which may extend
the repertoire of miRNA regulated genes involved in the development
and pathogenesis of uterine leiomyoma.
4. Materials and methods
4.1. Tissue samples
Portions of leiomyomata, approximately 2×3-cm sections from the
periphery distinct fromnormal tissue, andmatched unaffectedmyome-
trium were collected from 2 women who were undergoing hysterecto-
my for indications related to symptomatic leiomyomata. Tissue samples
were obtained from each leiomyoma and adjacent matched normal
myometrium. None of the patients had received any medical treatment
for their ﬁbroids. The tissues were collected at the University of Colorado
Hospital with prior approval by the Colorado Multiple Institutional Re-
view Board, under protocol number 03-642. Immediately after collection
in the operating room, a portion of the tissue was snap frozen and stored
in liquid nitrogen.4.2. RNA isolation
Aliquots (~5 g) frozen tissue sectionswere pulverized under liquid
nitrogen. Powdered tissue (50–100 mg) was placed in 1 mL TRIzol
(Invitrogen Life Technologies, Inc., Carlsbad, CA) and was then homoge-
nized with a Polytron probe (Brinkmann Instruments, Westbury, NY).
Total cellular RNAwas isolated from the tissues using TRIzol per manu-
facturer's instructions. The isolated RNA was quantitated with the
NanoDrop ND1000 spectrophotometer (NanoDrop Technologies,
Wilmington, DE), so that no greater than 100 μg was loaded on the
column during the DNase treatment. The RNA was DNase treated
(twice) using QiagenRNeasy Mini kit and QiagenRNase-Free DNase s
(Qiagen, Inc., Chatsworth, CA). Quality of puriﬁed RNA was assessed
on a RNA 6000 Nano Chip using an Agilent 2100 bioanalyzer (Agilent
Technologies, Germany).
4.3. Small RNA library construction and sequencing
Small RNA libraries and sequencing for each sample (control samples
B25N, B27N and leiomyoma samples B25L, B27L) were performed by LC
Sciences (Houston, TX). Brieﬂy, the small RNA libraries were generated
according to Illumina's sample preparation instruction. Total RNA sam-
ples were size-fractionated on a 15% tris-borate-EDTA-Urea polyacryl-
amide gel. RNA fragments of length 15–50 nt were isolated, quantiﬁed
following gel elution, and ethanol precipitated. The SRA 5′ adapter (Illu-
mina) was ligated to the aforementioned RNA fragments with T4 RNA
ligase (Promega). The ligated RNAs were size-fractionated on a 15%
tris-borate-EDTA-Urea polyacrylamide gel and RNA fragments of ~41–
76 ntwere isolated. The SRA 3′ adapter (Illumina) ligationwas then per-
formed followed by a second size-fractionation, as described above. RNA
fragments of size ~64–99 ntwere isolated through gel elution and etha-
nol precipitation. The ligated RNA fragmentswere reverse transcribed to
single-stranded cDNAs using M-MLV (Invitrogen) with RT-primers
recommended by Illumina. The cDNAs were ampliﬁed with pfx DNA
polymerase (Invitrogen) in 20 cycles of PCR using Illumina's small RNA
primer set. The resulting PCR products were puriﬁed on a 12% TBE poly-
acrylamide gel and a slice of gel between ~80 and 115 bps was excised.
This fractionwas eluted and the recovered cDNAswere precipitated and
quantiﬁed on Nanodrop (Thermo Scientiﬁc) and on TBS-380 mini-
ﬂuorometer (Turner Biosystems) using Picogreen® dsDNA quantization
reagent (Invitrogen). The concentrations of the samples were adjusted
to ~10 nM and a total of 10 μL used in sequencing reactions. The puriﬁed
cDNA libraries were used for cluster generation on Illumina's Cluster
Station and then sequenced on IlluminaGAIIx following the vendor's in-
structions. Raw sequencing reads were obtained using Illumina's Pipe-
line v1.5 software following sequencing image analysis by Pipeline
Firecrest Module and base-calling by Pipeline Bustard Module. The
extracted sequencing reads were stored in separate ﬁles for each library
and were then used in the following data analysis.
4.4. Reads ﬁlters and sequence analysis
After the raw sequence reads or sequenced sequenceswere extracted
from image data into a raw data ﬁle, tags were counted and a unique
family of sequences identiﬁed. In this step, the “impurity” sequences
due to sample preparation, sequencing chemistry and processing, and
the optical digital resolution of the sequencer detector were removed.
After the low quality ﬁlters were applied, adaptor sequences were
trimmed into a clean full length reads and formatted into a non-
redundant FASTA format (using FASTQ Toolkit; http://hannonlab.cshl.
edu/fastx_toolkit/download.html). Since each small RNA was repre-
sented by a unique sequence, the number of reads of this tag reﬂects
relative expression level of that RNA. The FASTA headers were com-
prised of the running number along with the count number of the cor-
responding sequence. Only small RNA sequences of 15 to 30 nt were
retained for further analysis.
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All unique sequence tags that passed the read ﬁlters were mapped
onto the reference human genome (hg19) using Bowtie [44] software
allowing at most one mismatch. Moreover, the unique sequences tags
were aligned against miRbase v17 [45,46], computationally predicted
human ncRNA and Rfam 9.1 (rfam.sanger.ac uk/), the Repeat Masker
pre-build (hg19) annotation and human genes UCSC annotation hg19
(genome.ucsc.edu/) to generate tag classiﬁcations for known miRNA,
degradation fragments of non-coding RNA, genomic repeats and
mRNA respectively. To ensure every unique small RNA tag mapped to
only one annotation class, we used the following priority rule: ncRNA
(Rfam)>miRNA(miRBase)>Repeats (RepeatMasker)>mRNA (RefSeq)
[47]. The fraction of total ribosomal RNA served as a quality control for
each sample. Usually it should be less than 40% in animal samples of
high quality. Tags that did notmap to any of the above reference annota-
tion sets or tags that could not be aligned to the genomewere termed as
unclassiﬁed.
4.6. Statistical analysis of differential miRNA expression
In order to determine differential miRNA expression between leio-
myoma (samples B25L and B27L) and myometrium (samples B25N
and B27N), expression data for known miRNAs produced by reads
count was used as input for the Bioconductor DESeq package [29].
DESeq uses a negative binomial distribution model to test for differ-
ential expression in deep sequencing datasets. The list of differentially
expressed miRNAs produced by DESeq was further ﬁltered to remove
miRNAs with less than 5 reads in all samples and retain those with
signiﬁcant differences pb0.05 and |log2 ratio|≥1.
4.7. Novel miRNA prediction
The novel miRNA prediction strategy is based on initial scanning of
read libraries with publically available software for prediction of novel
miRNAs from deep sequencing datasets — MIREAP (http://sourceforge.
net/projects/mireap/) and miRDeep [48] using their default parameters.
We further analyzed the output of the programs by in-house Perl script
(unpublished) that annotates all newly found genomic loci and discards
those that overlap with known miRNAs or known human ncRNA loci
fromRfam9.1 (rfam.sanger.ac uk/). Furthermore,we discarded predicted
miRNAs that had less than 5 total mapped reads.
Supplementary materials related to this article can be found online
at doi:10.1016/j.ygeno.2012.03.003.
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